This is especially relevant in light of the recent ASCO recommendations supporting routine ctESR1m testing in patients with metastatic ER + ve, HER2-ve BC progressing on hormonal therapy, supported in the UK with ctESR1m being added to the cancer test directory. Here, ERBB2 is linked to cancer.